Increased_VBN
natural_JJ
killer_NN
cell_NN
activity_NN
correlates_VBZ
with_IN
low_JJ
or_CC
negative_JJ
expression_NN
of_IN
the_DT
HER-2_NN
\/_CC
neu_NN
oncogene_NN
in_IN
patients_NNS
with_IN
breast_NN
cancer_NN
._.

BACKGROUND_NN
._.

Increased_VBN
expression_NN
of_IN
the_DT
HER-2_NN
\/_CC
neu_NN
oncogene_NN
in_IN
breast_NN
cancer_NN
correlates_VBZ
with_IN
decreased_VBN
estrogen_NN
receptor_NN
concentration_NN
and_CC
seems_VBZ
to_TO
be_VB
an_DT
important_JJ
prognostic_JJ
factor_NN
._.

The_DT
authors_NNS
investigated_VBD
whether_IN
there_EX
is_VBZ
a_DT
correlation_NN
between_IN
HER-2_JJ
\/_CC
neu_CD
expression_NN
and_CC
immunologic_JJ
parameters_NNS
representing_VBG
tumor_NN
defense_NN
in_IN
patients_NNS
with_IN
breast_NN
cancer_NN
._.

METHOD_NN
._.

A_DT
Western_NN
blot_NN
analysis_NN
was_VBD
used_VBN
to_TO
investigate_VB
HER-2_NN
\/_CC
neu_NN
expression_NN
,_,
whereas_IN
a_DT
chromium-release_NN
assay_NN
using_VBG
the_DT
K562_NN
cell_NN
line_NN
as_IN
target_NN
was_VBD
used_VBN
to_TO
measure_VB
natural_JJ
killer_NN
-LRB-_-LRB-
NK_NN
-RRB-_-RRB-
cell_NN
activity_NN
._.

RESULTS_NNS
._.

In_IN
patients_NNS
with_IN
breast_NN
cancer_NN
,_,
NK_NN
cell_NN
activity_NN
was_VBD
significantly_RB
higher_JJR
compared_VBN
with_IN
patients_NNS
with_IN
benign_JJ
tumors_NNS
-LRB-_-LRB-
P_NN
=_JJ
0.006_CD
-RRB-_-RRB-
or_CC
healthy_JJ
control_NN
subjects_NNS
-LRB-_-LRB-
P_NN
=_JJ
0.002_CD
-RRB-_-RRB-
._.

Moreover_RB
,_,
23.3_CD
%_NN
of_IN
patients_NNS
with_IN
breast_NN
cancer_NN
showed_VBD
an_DT
overexpression_NN
of_IN
HER-2_NN
\/_:
neu_NN
protein_NN
._.

Within_IN
this_DT
group_NN
of_IN
patients_NNS
,_,
NK_NN
cell_NN
activity_NN
was_VBD
significantly_RB
lower_JJR
-LRB-_-LRB-
45.6_CD
+_CC
\/_NN
-_:
16.1_CD
%_NN
-RRB-_-RRB-
compared_VBN
with_IN
the_DT
group_NN
with_IN
no_DT
HER-2_NN
\/_:
neu_CD
overexpression_NN
-LRB-_-LRB-
57.3_CD
+_CC
\/_CD
-_:
11.0_CD
%_NN
-RRB-_-RRB-
._.

NK_NN
cell_NN
activity_NN
did_VBD
not_RB
increase_VB
in_IN
patients_NNS
with_IN
HER-2_NN
\/_CC
neu_NN
overexpression_NN
._.

Thus_RB
,_,
there_EX
was_VBD
a_DT
statistically_RB
significant_JJ
correlation_NN
of_IN
cytolytic_JJ
effector_NN
cell_NN
function_VBP
with_IN
HER-2_NN
\/_:
neu_JJ
expression_NN
of_IN
the_DT
tumor_NN
-LRB-_-LRB-
P_NN
=_JJ
0.003_CD
-RRB-_-RRB-
,_,
and_CC
HER-2_NN
\/_CC
neu_JJ
overexpression_NN
correlated_VBN
with_IN
a_DT
negative_JJ
estrogen_NN
receptor_NN
status_NN
-LRB-_-LRB-
P_NN
=_JJ
0.005_CD
-RRB-_-RRB-
._.

CONCLUSION_NN
._.

These_DT
data_NNS
add_VBP
further_RB
evidence_NN
to_TO
previous_JJ
observations_NNS
from_IN
the_DT
authors_NNS
'_POS
laboratory_NN
that_IN
certain_JJ
tumor_NN
characteristics_NNS
may_MD
be_VB
associated_VBN
with_IN
reactions_NNS
of_IN
the_DT
host_NN
with_IN
breast_NN
cancer_NN

